February 27, 2017 09:21 AM ESTUpdated 10:32 AM
News Briefing

Pieris inks a li­cens­ing deal for Japan; Kindler joins Phar­ma Two B board with $30M raise; Am­pio plots new pain study

Shehla Shakoor

Managing Director

→ Boston-based Pieris $PIRS has op­tioned a li­cens­ing pact giv­ing AS­KA Phar­ma­ceu­ti­cal de­vel­op­ment and com­mer­cial­iza­tion rights for the ane­mia drug PRS-080 in Japan and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times